Management of secondary hyperparathyroidism in Italy: Results of the Italian FARO survey

Sandro Mazzaferro, Diego Brancaccio, Piergiorgio Messa, Vittorio E. Andreucci, Guido Bellinghieri, Roberto Bigazzi, Piergiorgio Bolasco, Anna Maria Costanzo, Umberto di Luzio Paparatti, Giuseppe Cannella

Research output: Contribution to journalArticlepeer-review


Aims: In recent years, treatment options for secondary hyperparathyroidism (SHPT) have increased (e.g., paricalcitol, calcimimetics). To determine the impact these new treatments have on achieving K/DOQI targets, an observational, prospective survey was undertaken. Methods: Four 6-month time-spaced surveys of 2,637 patients in 28 Italian dialysis units were performed. Patient demographic information; use of vitamin D or calcimimetics; and changes in parathyroid hormone (PTH), calcium (Ca) and phosphate (P) levels were evaluated. Results: Over the course of the survey, use of calcitriol decreased (from 62.1% at baseline to 44.5% at month 18; p

Original languageEnglish
Pages (from-to)225-235
Number of pages11
JournalJournal of Nephrology
Issue number2
Publication statusPublished - Mar 2011


  • Calcimimetics
  • Calcitriol
  • K/DOQI
  • Paricalcitol
  • Secondary hyperparathyroidism

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'Management of secondary hyperparathyroidism in Italy: Results of the Italian FARO survey'. Together they form a unique fingerprint.

Cite this